Clinexpert Kft.
- Address
- lock Available on a paid plan
Clinexpert Kft. - Multi-Specialty Clinical Research Center
Clinexpert Kft. is a comprehensive clinical research facility specializing in a diverse range of therapeutic areas, with particular expertise in inflammatory and immune-mediated disorders. The center conducts advanced Phase 2 and Phase 3 clinical trials, focusing on novel therapeutic agents and biosimilar evaluations across multiple disease states.
- Gastroenterology: Ulcerative colitis and Crohn's disease trials investigating multiple novel biologics and small molecules
- Dermatology: Atopic dermatitis studies including pediatric and adolescent populations with innovative immunomodulatory therapies
- Neurology: Multiple sclerosis and migraine prevention research, including pediatric migraine studies
- Cardiovascular and Metabolic Medicine: Atherosclerotic cardiovascular disease and lipid disorder management trials
The research center demonstrates significant capability in conducting respiratory disease trials, including studies for asthma and chronic obstructive pulmonary disease (COPD). Additional therapeutic focus areas include women's health conditions such as endometriosis-related pain and primary dysmenorrhea. Clinexpert Kft. maintains expertise in managing both short-term efficacy studies and long-term safety extension trials, with particular emphasis on evaluating biologics, oral small molecules, and biosimilar agents across various patient populations including pediatric and adolescent participants.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 132 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 125 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 28 by active trials.
- 1AstraZeneca AB6active
lock +27 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.14trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinexpert Kft.
lock Showing 1 of 129 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 132 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 4 | Unknown | 2021-08-16 | 2024-01-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.